Obesity’s Effects on the Immune System May Linger for Years

Key Takeaways

• Obesity drives CD4+ T cells into pro‑inflammatory effector memory state
• Weight loss normalizes fat but T‑cell inflammation persists weeks in mice
• Extended maintenance (12 weeks) restores T‑cell balance, suggesting years in humans
• DNA methylation of Bcl6 and Stk26 remains altered after diet reversal
• STK26‑driven autophagy is required for inflammatory Tem expansion

Pulse Analysis

Obesity is increasingly recognized as a driver of chronic low‑grade inflammation, largely through reshaping the immune landscape of adipose tissue. Recent work highlights that the shift is not merely metabolic but epigenetic: helper CD4+ T cells adopt an effector‑memory (Tem) phenotype that persists after the excess fat is lost. This "obesity memory" is encoded in DNA methylation patterns, notably at the Bcl6 and Stk26 loci, which keep these cells primed for inflammatory responses. The phenomenon mirrors clinical observations where patients who lose weight still face elevated risks of type‑2 diabetes and certain cancers, suggesting that the immune system retains a scar from prior excess.

In mouse models, researchers compared three diet regimens—standard chow, continuous high‑fat diet, and high‑fat followed by chow recovery. Although the recovery group regained normal adipose mass, their Tem cells remained elevated for up to 14 weeks, only normalizing after a prolonged 12‑week maintenance phase. Methylation profiling revealed 104 genes with persistent changes, with hypomethylation of Bcl6 and Stk26 correlating with heightened autophagy and Tem fitness. Functional experiments showed that knocking out Stk26 blunted autophagy and reduced Tem expansion, establishing a causal link between this pathway and the sustained inflammatory state.

Human translation remains tentative. Short‑term interventions—six months of GLP‑1 agonist therapy or a 10‑week exercise program—did not reset T‑cell phenotypes despite measurable weight loss. This lag underscores the need for therapies that directly target the epigenetic and autophagic mechanisms sustaining obesity‑induced immune memory. Agents such as SGLT2 inhibitors, already noted for anti‑inflammatory effects, may accelerate the reversal of Tem dominance. Future research must delineate the timeline of immune normalization in people and evaluate whether combined metabolic and immunologic treatments can shorten the years‑long “obesity memory” window.